You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
希維奧®多個治療血液腫瘤的方案獲得NCCN、CSCO、ESMO指南及循證研究的重磅推薦和支持
格隆匯 12-20 17:18

格隆匯12月20日|德琪醫藥-B(6996.HK):中國血液腫瘤事業部負責人於立新先生在電話會議中表示,作為全球首款且唯一一款口服型XPO1抑制劑,希維奧®已深受國際認可,多個治療血液腫瘤的方案已獲得指南及循證研究的重磅推薦和支持。

截至2021年,其4個治療骨髓瘤和1個治療淋巴瘤的方案已被納入美國國家綜合癌症網絡(NCCN)指南、4個治療骨髓瘤和淋巴瘤的方案已被納入中國臨牀腫瘤協會(CSCO)診療指南、2個治療骨髓瘤的方案已被納入歐洲腫瘤內科學會(ESMO)指南。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account